Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Regulus Therapeutics Inc (NASDAQ:RGLS)

5.29
Delayed Data
As of Jun 24
 -0.45 / -7.84%
Today’s Change
4.96
Today|||52-Week Range
11.59
-39.33%
Year-to-Date
Can These Upstarts Knock Gilead Sciences Off Its Perch?
Jun 22 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close5.74
Today’s open5.41
Day’s range5.25 - 5.60
Volume1,803,135
Average volume (3 months)915,148
Market cap$279.2M
Dividend yield--
Data as of 4:00pm ET, 06/24/2016

Growth & Valuation

Earnings growth (last year)+16.28%
Earnings growth (this year)-42.48%
Earnings growth (next 5 years)--
Revenue growth (last year)+170.69%
P/E ratioNM
Price/Sales21.60
Price/Book2.25

Competitors

 Today’s
change
Today’s
% change
ARDXArdelyx Inc-0.23-2.78%
PRTKParatek Pharmaceutic...-0.56-4.17%
AKBAAkebia Therapeutics ...-0.32-4.11%
ADXSAdvaxis Inc-0.26-3.18%
Data as of 4:00pm ET, 06/24/2016

Financials

Next reporting dateAugust 9, 2016
EPS forecast (this quarter)-$0.38
Annual revenue (last year)$20.8M
Annual profit (last year)-$55.7M
Net profit margin-268.55%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
President, Chief Executive Officer &
Director
Paul C. Grint
COO, Principal Financial &
Accounting Officer
Joseph P. Hagan
Corporate headquarters
San Diego, California

Forecasts

Partner Offers

Search for Jobs